A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
2024年5月22日 - 11:23PM
Trial Equity and Miller Tanner Associates (MTA) are excited to
announce a groundbreaking partnership aimed at expanding education
and participation across diverse patient groups, in a strategic
move to address the crucial gap in clinical trial diversity. This
collaboration will co-market Trial Equity’s innovative Clinical
Trial Diversity Training to pharmaceutical sponsors, CROs, and site
networks, leveraging MTA's extensive global reach and expertise in
event management within the healthcare sector.
Miller Tanner Associates, a Women’s Business Enterprise National
Council (WBENC)-certified leader in life sciences and corporate
event planning, brings its sterling reputation and logistical
prowess to this partnership. Known for its personalized expertise
and tailored solutions in managing Face-to-Face, Virtual, and
Hybrid meetings, MTA will now also promote Trial Equity's eLearning
course through its Event Content Management (ECM) platform, VALTs
(Virtual Assessment, Learning & Training source). MTA will
further empower healthcare professionals (HCPs) to implement
diversity in clinical trials by offering Trial Equity’s vital
diversity workshops at Investigator Meetings.
"Partnering with Miller Tanner Associates was a strategic
choice, driven by their deep expertise in life sciences and
masterful event planning,” shared Dr. Otis Johnson, Co-founder,
Trial Equity. “Their innovative VALTs platform and extensive global
experience are key to effectively delivering our Clinical Trial
Diversity Training worldwide. This partnership marks a critical
step toward ensuring future medical breakthroughs are effective and
accessible to everyone, truly reflecting the diverse communities we
aim to serve.”
Both the eLearning course and in-person diversity workshop
content, developed by Trial Equity, offer a comprehensive
curriculum designed to broaden the representation and effectiveness
of clinical trials. The course directly addresses disparities
identified in recent studies, including findings from the Tufts
Center for the Study of Drug Development, which highlighted the
insufficient infrastructure for engaging and recruiting diverse
patient populations.
“Diversity in clinical trials is a significant challenge for our
industry and one that demands urgent action,” said Scott Nodolf,
Chief Revenue Officer, MTA. “MTA is proud to partner with Trial
Equity to meet the evolving needs of our customers with this new
service offering and drive meaningful transformation of our
industry.”
Together, Trial Equity and Miller Tanner Associates are setting
new standards in clinical trial diversity, paving the way for a
future where medical research is truly inclusive.
About Trial Equity
Trial Equity is committed to ensuring that all people have safe
and effective medicines by providing inclusive access to medical
research opportunities. By equipping professionals with the
necessary resources and education, Trial Equity aims to mirror the
disease population in clinical trials, enhance drug development
quality, and accelerate patient recruitment.
About Miller Tanner Associates (MTA)
Miller Tanner Associates is a full-service event planning
company with over 27 years of experience in the pharmaceutical,
biotech, and medical device industries. With a track record of
delivering nearly 3,000 successful Investigator Meetings globally,
MTA's dedication to excellence and customer service is unmatched in
the industry. As a WBENC-certified Women's Business Enterprise, MTA
is also a proud advocate for diversity and inclusivity in all
business aspects.
For more information on this partnership, the Clinical Trial
Diversity eLearning Course, or to arrange a diversity workshop,
please visit Miller Tanner Associates or Trial Equity.
Contacts:
Miller Tanner Associates: Scott Nodolf,
scott.nodolf@millertanner.com
Trial Equity: Otis Johnson, otis.johnson@trialequity.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e37d552-5fb5-4b68-93cc-0d58195a46a8